Infliximab Dose Rounding Pratices in Pediatric Inflammatory Bowel Disease

Kelly C. Sandberg; Benjamin H. Shpeen; Sally J. Eder; Muhammad Dhanani; Sarah J. Clark; Gary L. Freed; Jeremy Adler

Infliximab Dose Rounding Pratices in Pediatric Inflammatory Bowel Disease

Kelly C. Sandberg, Benjamin H. Shpeen, Sally J. Eder, Muhammad Dhanani, Sarah J. Clark, Gary L. Freed, Jeremy Adler

Wright State University

Research output: Contribution to journal › Article › peer-review

Abstract

Infliximab (IFX) is commonly used to treat Inflammatory Bowel Disease (IBD). IFX is supplied in 100mg vials and remains expensive. Dosing usually starts at 5mg/kg, and is commonly rounded up or down. The scope of dosing practices is unknown. Under-dosing may place patients at risk for exacerbation of IBD. Over-treatment potentially carries increased risk of infectious and malignant complications. We aimed to characterize IFX dosing practices among pediatric IBD practitioners participating in the ImproveCareNow Network.

Original language	American English
Journal	Journal of Pediatric Gastroenterology and Nutrition
Volume	55
State	Published - Oct 1 2012

Disciplines

Medical Specialties
Medicine and Health Sciences
Pediatrics

Access to Document

Infliximab Dose Rounding Pratices in Pediatric Inflammatory BowelFinal published version, 1.24 MBLicense: Unspecified

Cite this

@article{edf3512adb4643cc95e1d578742c1ea1,

title = "Infliximab Dose Rounding Pratices in Pediatric Inflammatory Bowel Disease",

abstract = " Infliximab (IFX) is commonly used to treat Inflammatory Bowel Disease (IBD). IFX is supplied in 100mg vials and remains expensive. Dosing usually starts at 5mg/kg, and is commonly rounded up or down. The scope of dosing practices is unknown. Under-dosing may place patients at risk for exacerbation of IBD. Over-treatment potentially carries increased risk of infectious and malignant complications. We aimed to characterize IFX dosing practices among pediatric IBD practitioners participating in the ImproveCareNow Network.",

author = "Sandberg, {Kelly C.} and Shpeen, {Benjamin H.} and Eder, {Sally J.} and Muhammad Dhanani and Clark, {Sarah J.} and Freed, {Gary L.} and Jeremy Adler",

year = "2012",

month = oct,

day = "1",

language = "American English",

volume = "55",

journal = "Journal of Pediatric Gastroenterology and Nutrition",

}

TY - JOUR

T1 - Infliximab Dose Rounding Pratices in Pediatric Inflammatory Bowel Disease

AU - Sandberg, Kelly C.

AU - Shpeen, Benjamin H.

AU - Eder, Sally J.

AU - Dhanani, Muhammad

AU - Clark, Sarah J.

AU - Freed, Gary L.

AU - Adler, Jeremy

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Infliximab (IFX) is commonly used to treat Inflammatory Bowel Disease (IBD). IFX is supplied in 100mg vials and remains expensive. Dosing usually starts at 5mg/kg, and is commonly rounded up or down. The scope of dosing practices is unknown. Under-dosing may place patients at risk for exacerbation of IBD. Over-treatment potentially carries increased risk of infectious and malignant complications. We aimed to characterize IFX dosing practices among pediatric IBD practitioners participating in the ImproveCareNow Network.

AB - Infliximab (IFX) is commonly used to treat Inflammatory Bowel Disease (IBD). IFX is supplied in 100mg vials and remains expensive. Dosing usually starts at 5mg/kg, and is commonly rounded up or down. The scope of dosing practices is unknown. Under-dosing may place patients at risk for exacerbation of IBD. Over-treatment potentially carries increased risk of infectious and malignant complications. We aimed to characterize IFX dosing practices among pediatric IBD practitioners participating in the ImproveCareNow Network.

UR - https://corescholar.libraries.wright.edu/pediatrics/488

M3 - Article

VL - 55

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

ER -

Infliximab Dose Rounding Pratices in Pediatric Inflammatory Bowel Disease

Abstract

Disciplines

Access to Document

Other files and links

Cite this